Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a10dc651e733b8d5a1ec5684b812362 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43585ab0b60258bf44ec4c36f058522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0b0604cb3452f80776a56176a10d10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_922dbc49f2821da0d14782d9d28d2640 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47899c334a2656edf373c53cc8327b6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc4927353e64095b84be65d59fda2824 |
publicationDate |
2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019052975-A1 |
titleOfInvention |
IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS |
abstract |
The present invention relates to an immunogenic composition comprising an HCMV gB antigen, HCMV pentameric complex antigen gH / gL / UL128 / UL130 / UL131 and Th1 inducing adjuvant. The invention further relates to the immunogenic composition for use as an HCMV vaccine. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022090359-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022023416-A1 |
priorityDate |
2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |